Home » Newsletters » BioWorld Science

BioWorld Science

July 23, 2015

View Archived Issues

Prevention of HIV transcription from latency by Tat inhibitor

BioRestorative Therapies to evaluate encapsulation technology for use in metabolic program

Dauntless Pharmaceuticals closes series A financing, licenses technology from Aegis

KalVista Pharmaceuticals raises funds to advance plasma kallikrein inhibitor pipeline

Merck & Co.'s Keytruda approved in Europe for advanced melanoma

Novartis presents milestones of second quarter 2015

Discovery and optimization of a pan-RET/VEGFR-2 dual inhibitor for single-agent polypharmacology

New organotypic brain slice culture model helps elucidate Alzheimer's disease pathology

Horizon Pharma increases share offer for Depomed

CNGA2 KO mice show AD-like pathological features

Beaufour Ipsen Tianjin Pharmaceutical describes AR degraders

Intra-Cellular Therapies plans phase III program for ITI-007 in bipolar depression

Polyphor reports selective elastase inhibitors

Catalyst initiates rolling NDA for Firdapse in LEMS

West China Hospital, Sichuan University reports short-acting anesthesic

Novartis files sBLA for ofatumumab as maintenance therapy for relapsed CLL

Alectos Therapeutics designs GCase inhibitors

Erum Biotechnologies patents PTP-1B inhibitors

Vidasym's phosphate binder VS-505 enters phase I/II trial

Phase I study investigates T4 immunotherapy for head and neck cancer

Xoma reports data from phase III EYEGUARD-B study

Roche Diagnostics launches HTLV blood test

AMAG Pharmaceuticals obtains option to acquire digoxin immune fab for pre-eclampsia

NIH funds collaborative project to develop measures of social impairment in autism

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...